Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 2,514 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Corona Virus Infection
Interventions: Zotatifin, Placebo; Drug
Lead sponsor: Effector Therapeutics; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Anniston, Alabama • Cullman, Alabama • Tampa, Florida + 1 more

Conditions: Healthy
Interventions: Nalmefene; Drug
Lead sponsor: Tharimmune Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Unprotected Sex, Contraceptive Usage
Interventions: Pulse; Behavioral
Lead sponsor: Child Trends; Other
Eligibility: 18 Years to 20 Years · Female only
Enrollment: 2,317 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Treatment A: 400 mg Pacritinib P3CT, Treatment B: 400 mg of pacritinib FMI; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy
Interventions: Lu AG06479, Placebos; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: tasimelteon, Rifampin, Ketoconazole; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Nicotine Vaping, Nicotine, Vaping
Interventions: CA35, CM35, Cig; Other
Lead sponsor: Philip Morris Products S.A.; Industry
Eligibility: 24 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Sunburn, Erythema, Sun Protection
Interventions: Goal attainment; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: Danuglipron, Cyclosporine, Itraconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Parkinson Disease
Interventions: Tavapadon, Carbamazepine; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pain
Interventions: Suzetrigine; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Short Bowel Syndrome
Interventions: NM-002; Drug
Lead sponsor: 9 Meters Biopharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Autism Spectrum Disorder
Interventions: Mounted Human-equine Interaction, Unmounted Human-equine Interaction, No-Horse Control; Behavioral
Lead sponsor: Colorado State University; Other
Eligibility: 6 Years to 16 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Traumatic Brain Injury
Interventions: MRI Diagnostic; Device
Lead sponsor: GE Healthcare; Industry
Eligibility: 15 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Keratoconus, Corneal Ectasia
Interventions: Riboflavin 0.1% ophthalmic solution, CCL-VARIO UV lamp, CCL-VARIO at 18 mW/cm2; Drug · Device
Lead sponsor: Robert Mack, M.D.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Hoffman Estates, Illinois

Conditions: Reasoning Training
Interventions: Telehealth Reasoning Training; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 65 Years to 100 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy Subjects
Interventions: CPI-444 Capsules, CPI-444 Tablets; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pulmonary Invasive Fungal Infections, Pulmonary Invasive Aspergillosis
Interventions: Non-Invasive Testing for PIFI; Diagnostic Test
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 120 Days to 21 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 32
States / cities: Little Rock, Arkansas • La Jolla, California • Orange, California + 28 more

Conditions: Traumatic Brain Injury, Headaches Posttraumatic, Trauma, Pain, Acute
Interventions: Virtual Reality Session (VR Blu), Tablet-based Session (Tablet Blu), Use of Virtual Reality Head Mounted Display without Content (VR Blank); Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
Interventions: Product A, Product B, Product C, Product D, Product E, Product F, Product N; Other
Lead sponsor: RAI Services Company; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hip Arthropathy
Interventions: Modified MRI; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: ALXN1840 Enteric-coated Tablet, ALXN1840 Non-coated Capsule, Omeprazole; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Depth of Focus
Interventions: No intervention; Other
Lead sponsor: Johnson & Johnson Surgical Vision, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Bakersfield, California • Sioux City, Iowa • Brecksville, Ohio + 1 more

Search by objective public record fields.

Intravenous Zotatifin in Adults With Mild or Moderate COVID-19

An Evaluation of The Absolute Bioavailability of TH104

HIV Expression in Patients With Low Viral Load on Highly Active Antiretroviral Therapy (HAART)

The Evaluation of Pulse: A Mobile Health App and Teen Pregnancy Prevention Program

To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects

Safety and Tolerability of Lu AG06479 in Healthy Young Men

Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.

Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes

UV Exposure Assessed With Wearable Sensor and Sun Protection

A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults.

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

Proof of Concept Study in Patients With Short Bowel Syndrome

Effects of Mounted vs Unmounted Human-Equine Interaction on Autistic Youth

Advanced MRI Applications for Mild Traumatic Brain Injury - UCSF

Study of the Safety and Effectiveness of Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2

Feasibility and Effectiveness of a Telehealth-Delivered Inductive Reasoning Training Program for Older Adults

Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects

Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections

Adjunct VR Pain Management in Acute Brain Injury

Abuse Liability for Five Modern Oral Nicotine Products

Optimized MRI of Patients With Hip Arthroplasty

A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults

Prospective, Multi-center, Non-interventional, Open Label, Randomized (Depth of Focus Testing Sequences), Clinical Study